drugset / Trial / NCT06094140
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Phase 2
Active not recruiting
20 enrolled
Australasian Gastro-Intestinal Trials Group
The University of New South Wales · collabWalter and Eliza Hall Institute of Medical Research · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Timeline
- Start
- 2022-05-20
- Primary completion
- 2024-06-30
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Background | Calcium folinate | Unknown | 50 mg | Intravenous |
| Background | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |